Project Grant RF1AG081812
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$1.6M
Funding Federal Agency
Office of the Director
Awarding Federal Agency
National Institute on Aging
Federal Grant Program
93.310
Assistance Type
Project Grant
Place of Performance
College Station, TX 77843, USA
Similar Awards
This $3.44 million project grant from the Department of Health and Human Services National Institutes of Health Office of the Director, under the Trans-NIH Research Support program (CFDA 93.310), will fund research at the University of Massachusetts Medical School to suppress aneuploidy-associated phenotypes in Down syndrome. Specifically, the researchers will identify the mechanisms by which an extra copy of chromosome 21 affects nuclear structure and function in cells, investigate how...
This $3.386 million project grant from the National Institutes of Health's Trans-NIH Research Support program (CFDA 93.310) will fund research at Beth Israel Deaconess Medical Center to develop a potential treatment for Down syndrome. The grantee will assess the efficiency of using a modified CRISPR approach and single nucleotide polymorphism-based guide RNA targeting to silence one of three copies of human chromosome 21 in the Tc1 mouse model of Down syndrome. If successful, this research could...
This federal Project Grant award of $2,357,335.00, funded by the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), supports research to understand neuronal dysfunction in Down syndrome and its relationship to Alzheimer's disease. The project utilizes advanced in vitro and in vivo models, including cortical organoids and assembloids, to investigate cellular, transcriptomic, and neuronal activity changes driven by trisomy in Down...
This federal Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) to Texas A&M AgriLife Research is focused on investigating the role of the SIM2 gene in regulating mitochondrial dysfunction in Down syndrome. The $1,960,246 award, with a project period running from September 2023 to August 2026, supports three specific aims: 1) determining how SIM2 interacts with and regulates the mitochondrial respiratory complex, 2) evaluating...
The National Institutes of Health (NIH) Office of the Director awarded a $1,896,457 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a comprehensive study on brain development in Down syndrome (DS) during fetal and early postnatal ages. The research aims to: 1) Confirm and expand upon previous findings of early brain abnormalities in DS using ex vivo MRI and...
This $5.2 million project grant from the Department of Health and Human Services National Institutes of Health Office of the Director, under the Trans-NIH Research Support program, will fund research at the University of Colorado Denver to study neurovascular dysfunction in individuals with Down syndrome revealed by traumatic brain injury. Over three years, the collaborative multi-principal investigator team will establish how trisomy 21-related cellular defects and candidate genes exacerbate...
This $727,160 Project Grant award from the National Institute of Child Health and Human Development's Child Health and Human Development Extramural Research program (CFDA 93.865) supports research to characterize early cognitive growth and identify biomedical factors associated with severe or profound intellectual disability in children with Down syndrome. The project will recruit 90 children with Down syndrome to undergo comprehensive cognitive and developmental assessments over 3 annual waves,...
The National Institute of Child Health and Human Development (NICHD) awarded a $2,010,230 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to the University of California, San Diego (UCSD) on July 15, 2024. The grant will fund a comprehensive investigation into the intricate nuclear-metabolic interplay in Down Syndrome (DS), with the goal of characterizing and modulating the nuclear-metabolic axis during neurodevelopment. The research will focus on three key...
This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $429,000.00 to the Regents of the University of Michigan to conduct research on the molecular mechanisms underlying changes in inhibitory synapses in Down syndrome. The primary goal is to discover how the overexpression of the Down Syndrome Cell Adhesion Molecule (DSCAM) gene, resulting from...
This $306,623 Project Grant award from the National Institutes of Health (CFDA 93.310 - Trans-NIH Research Support) aims to enhance treatment for myeloid leukemia associated with Down syndrome (ML-DS). The key objectives are: 1) Determine the role of the Down syndrome bone marrow microenvironment in ML-DS therapy responses, and 2) Investigate using hydroxyurea to enhance cytarabine activity against ML-DS cells. The project seeks to improve understanding of the mechanisms underlying the high cure...